Staphylococcus aureus bacteremia (SAB) is associated with significant mortality. Recent reports indicate that the incidence of invasive S. aureus infections has increased since the start of the COVID-19 pandemic. The impact of recent COVID-19 infection on clinical outcomes of patients with SAB is unknown. We performed a retrospective study investigating outcomes associated with SAB in patients with recent COVID-19 infection (SAB-C) versus patients with SAB without a recent positive COVID-19 test (SAB-N). We used data collected by the Georgia Emerging Infections Program (EIP), a CDC- funded invasive S. aureus surveillance study in the 8-county Atlanta metro area to identify all patients with SAB between 2020-2021. SAB cases were linked to COVID-19 test results from the Georgia Notifiable Disease Reporting data to collect patient COVID-19 test results within 90-days of the initial positive blood culture. For subjects experiencing > 1 episode of SAB, only the first episode was evaluated to ensure independence of observations. Comparisons were made using Kruskal-Wallis test and Fisher’s exact test as appropriate. Statistical significance was set at P=0.05. SAB-C is associated with high mortality. Further research is needed to understand additional factors contributing to this high mortality rate including source of infection, infecting strain, and underlying host immune factors. All Authors: No reported disclosures